Figure 2From: Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvementReduction of the Items contributing to the ASAS-Score during 12 weeks of blinded treatment. (A) Spinal inflammation Score, (B) Pain Score, (C) Physical function (Bath ankylosing spondylitis functional index), (D) Patient's Global Assessment of disease activity. The median is given.Back to article page